- ITEK -65.6% (announces top-line results of MATrX-1 did not achieve its primary endpoint of superiority in reduction of intraocular pressure compared with placebo at all 12 time points; will wait for the full results from MATrX-1)
- TKC -4.4% (following Turkish terrorist attack)
- MDT -1.3% (downgraded to Neutral from Buy at BofA/Merrill, downgraded to Neutral from Overweight at JP Morgan, downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt $77)
- NOK -1.3% (downgraded to Perform at Oppenheimer)
- KORS -1.0% (downgraded to Neutral from Overweight at Piper Jaffray)
- ANF -0.9% (downgraded to Underperform from Perform at Oppenheimer, downgraded to Hold from Buy at Jefferies)
- Arlington Asset Investment (AI) files for $750 mln mixed securities shelf offering
- Axovant (AXON) files for $750 mln mixed securities shelf offering
- Biostar Pharma (BSPM) files for offering of 346,429 share common stock issuable upon the exercise of outstanding warrants previously issued
- Clean Diesel Technologies (CDTI) files for 6,232,750 common stock offering by selling stockholders
- Clovis Oncology (CLVS) files for common stock offering by the co and/or selling stockholders; terms not disclosed. Co later announced an underwritten public offering of shares of its common stock to raise aggregate proceeds of about $175 mln.
- Professional Diversity Network (IPDN) files for offering of 246,445 shares of common stock issued upon the exercise of warrants to purchase our common stock by selling stockholder
- Novavax (NVAX) files for $125 mln mixed securities shelf offering and $75 mln at-the-market offering pursuant to a sales agreement with FBR Capital
- Ryerson (RYI) files for 21,037,500 share common stock offering by selling stockholders
- 22nd Century Group (XXII) files for $100 mln mixed securities shelf offering
- Parkervision (PRKR) entered into an At Market Issuance Sales Agreement to sell common stock having an aggregate offering price of up to $10 mln through FBR
- StoneMor Partners LP (STON) announces $20 mln private placement of 2,332,878 common units representing lp interests to StoneMor GP Holdings, the sole member and owner of the general partner of the Partnership
- Kopin (KOPN 2.84) will sell 7.339 mln shares to Goertek for $3.25/share in conjunction w/ partnership
- DEPO +12.4% (DepoMed could still be acquired by KKR (KKR), according to NY Post)
- CEL +12.2% (Cellcom Israel updates on negotiations w/ third parties interested in purchasing Golan Telecom's share capital and a liquidation request filed by the co against Golan Telecom)
- FNBC +10.3% (First NBC Bank to sell nine branches and certain assets and liabilities to Hancock Holding's Whitney Bank)
- ALJ +8.9% (Delek US Holdings (DK) to acquire remaining 53% of outstanding shares it doesn't already own in ALJ USA for about $12.13/share or total equity value of about $464 mln)
- XRX +7.8% (after spinnig off Conduent (CNDT), Credit Suisse upgraded to Outperform)
Financials showing relative strength: CS +4.8%, BCS +3.0%, BAC +2.0%, C +1.6%.
Brazil ADRs extending recent gains; iShares Brazil ETF (EWZ +1.6%): GGB +8.6%, PBR.A +5.2%, BBL +3.7%, VALE +3.9%, VALE +3.4%.
- KOPN +7.4% ( enters a relationship w/ Goertek; will sell 7,339,000 shares of its common stock to Goertek at $3.25/share)
- CDTI +7.0% (ticking higher; files for 6,232,750 common stock offering by selling stockholders)
- ARRY +5.4% (still checking)
- AMD +1.7% (positive Barron's mention)
- NVDA +1.7% (still checking)
- FIT +1.6% (announced the addition of Fitbit Charge 2 into the recently expanded UnitedHealthcare (UNH) Motion wellness program)
- IHG +3.8% (upgraded to Overweight from Equal Weight at Barclays)
- GRPN +3.0% (upgraded to Sector Perform from Underperform at RBC Capital Mkts)
- SRPT +2.8% (upgraded to Buy from Neutral at Janney; $65 tgt)
January 3, 2017
MAKOR - Share Class Report
Good morning and happy new year !
Please find below our most recent share class report dated 3/1/2017.
Our favorite trades remain the following:
+ RDSA LN/ - RDSB LN, with a catalyst (see our extensive discussions on this trade).
+ REN NA / - REL LN vs – UNA NA / + ULVR LN (combined)
+ CCL LN / - CCL US
– FOXA US / + FOX US
– UHRN SW / + UHR VX
Makor Capital
11 Menachem Begin St., 26th FL
Ramat Gan 52681
ISRAEL
Tel +972 3 5453 762Fax +972 3 7162 680
Research Disclaimer
This publication has been prepared by Makor Capital Limited (“Makor Capital”) and is intended for professional or qualified investors only. Makor Securities London Ltd (“Makor Securities”)is distributing this material to its clients who are Eligible Counterparties or Professional Clients under FCA Rules. It may also be disseminated to persons who are Investment Professionals within the meaning of the Financial Services and Markets Act 2000 (Financial Promotion Order 2005). In the United States, Makor Capital only distributes this material to major US institutional investors (as that term is defined in Rule 15a-6 of the Securities and Exchange Act of 1934) and to SEC-registered broker-dealers or banks acting in a broker–dealer capacity. This material is not intended for distribution to any other persons and should not be redistributed. If you do not fall into any of these categories you should disregard it.
This material is a marketing communication. It is not investment research and has not been prepared in accordance with legal requirements designed to promote the independence of investment research. It is not subject to any prohibition on dealing ahead of the dissemination of investment research under U.K. law. This material is not a research report and is not intended to be a research report as defined under U.S. securities laws and regulations. This material is not intended to provide information reasonably sufficient upon which to base any investment decision.
This material does not take into account the particular investment objectives, financial situation or needs of individual clients or other recipients. Before acting on this material, clients and other recipients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.
This material should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action.
In the United States, Makor Capital does not offer securities services to U.S. persons except pursuant to SEC Rule 15a-6 only to major US institutional investors and SEC registered broker-dealers or banks acting in a broker–dealer capacity. Transactions in the United States must be effected through the U.S. broker-dealer, Oscar Gruss & Son Incorporated. Oscar Gruss & Son has not prepared, reviewed or distributed this material.
Some of this material is produced by providers which Makor Securities believes to be reliable, but Makor Securities does not warrant or represent (expressly or impliedly) that it is accurate, complete, not misleading or as to its fitness for the purpose intended and it should not be relied upon as such.
Opinions expressed will be the current opinions of those producing this material as of the date appearing on this material only. We expect those producing the material in this publication to update it on a timely basis but can give no undertaking that they will do so and regulatory compliance or other reasons may prevent them from doing so (or us from disseminating updated material).
Members and employees of Makor Securities London Ltd, employees of Makor Capital, Makor Capital Markets may from time to time have long or short positions in securities, warrants, futures, options, derivatives or other financial instruments referred to in this material. For Makor Securities, this information is set out in our Conflicts of Interest Policy which is available on request. Policies for the production of research from other research providers are available on request. Unless otherwise stated, share prices provided within this material are as at the close of business on the day prior to the date of the material.
Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without prior consent. This material is issued for general information and discussion purposes only. None of Makor Securities, Makor Capital, Makor Capital Markets accepts liability whatsoever for any direct, indirect or consequential loss or damage of any kind arising out of the use of all or any of this material.
The services, securities and investments discussed in this material may not be available to, nor are suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk, including the risk of capital loss. Past performance is no guide to future performance. In relation to securities denominated in foreign currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable.
All investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk, including the risk of capital loss. Past performance is no guide to future performance. In relation to securities denominated in foreign currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable.
Entities
Makor Securities London Ltd is authorised and regulated by the Financial Conduct
Authority (FCA registration number 625054)
Makor Capital, company number 514456466, is incorporated in Israel and is a 100% held
subsidiary of Makor Holdings Pte Ltd incorporated in Singapore.
Makor Capital Markets SA, company number CH-660.2.999.011-0 is incorporated in Switzerland
and is also a 100% held subsidiary of Makor Holdings Pte Ltd.
Having trouble viewing this email? Click here
lchekroun@makor-cm.comThis email was sent to by Research@Makor-Capital.com
V.I.Plus e-mail marketing